MercoPress, en Español

Montevideo, November 18th 2018 - 12:17 UTC

Abbot Laboratories will pay US$ 25 million for bribing doctors to prescribe TriCor

Saturday, October 27th 2018 - 08:46 UTC
Full article
 Abbott improperly promoted TriCor for purposes other than those approved by FDA including as a treatment to reduce cardiac health risks in diabetic patients Abbott improperly promoted TriCor for purposes other than those approved by FDA including as a treatment to reduce cardiac health risks in diabetic patients
The U.S. Justice Department announced the settlement, which resolves claims first raised in a whistleblower lawsuit filed in federal court in Philadelphia in 2009 The U.S. Justice Department announced the settlement, which resolves claims first raised in a whistleblower lawsuit filed in federal court in Philadelphia in 2009

Abbot Laboratiories AbbVie Inc will pay a total of US$25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

The U.S. Justice Department on Friday announced the settlement, which resolves claims first raised in a whistleblower lawsuit filed in federal court in Philadelphia in 2009 by a former Abbott sales representative. AbbVie was spun out of Abbott in 2013.

Neither company, both of which are based in Chicago, admitted to wrongdoing as part of the settlement. AbbVie in a statement said the settlement concerned sales and marketing practices that occurred over a decade ago.

“The company determined it was in its best interest to resolve these allegations, rather than engage in protracted litigation, and focus on current business priorities,” AbbVie said.

The lawsuit alleged that from 2006 to 2008, Abbott, through its sales representatives, provided physicians kickbacks in the form of gift baskets, gift cards and other items in order to encourage them to write prescriptions for TriCor.

The lawsuit claimed that Abbott also retained healthcare providers for consulting services and speaking engagements in order to induce or reward doctors for writing prescriptions for the drug.

Abbott also improperly marketed and promoted TriCor for purposes other than those approved by the U.S. Food and Drug Administration, including as a treatment to prevent or reduce cardiac health risks in diabetic patients, the lawsuit said. 

The lawsuit was filed by Amy Bergman, a former Abbott sales representative, under the False Claims Act, which allows whistleblowers to sue companies on the government’s behalf to recover taxpayer money paid out based on fraudulent claims.

The government may intervene in such cases, but chose not to in this case, leaving Bergman to litigate it on her own prior to the settlement’s being announced. As a reward, Bergman will receive US$ 6.5 million as her share of the settlement.

The case is U.S. ex rel. Amy Bergman, et al. v. Abbott Laboratories, U.S. District Court, Eastern District of Pennsylvania, No. 09-04264.

Top Comments

Disclaimer & comment rules

Commenting for this story is now closed.
If you have a Facebook account, become a fan and comment on our Facebook Page!